Angiogenic activity of sera from interstitial lung disease patients in relation to clinical and radiological changes

European Journal of Medical Research

Volumn 14, Issue SUPPL.4, 2009, Pages 259-264

  Zielonka, T M ^a   Demkow, U ^a   Zycinska, K ^a   Filewska, M ^b   Bialas, B ^b   Kus, J ^b   Radzikowska, E ^b   Remiszewski, P ^b   Szopinski, J ^b   Soszka, A ^b   Wardyn, K A ^a   Skopinska Rozewska, E ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b NATIONAL TUBERCULOSIS AND LUNG DISEASES RESEARCH INSTITUTE   (Poland)

Author keywords

angiogenesis; clinical symptoms; interstitial lung diseases; radiological changes

Indexed keywords

ADOLESCENT; ADULT; AGED; ANGIOGENESIS; ARTICLE; BLOOD; FEMALE; HUMAN; INTERSTITIAL LUNG DISEASE; MALE; MIDDLE AGED; RADIOGRAPHY;

ADOLESCENT; ADULT; AGED; FEMALE; HUMANS; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; NEOVASCULARIZATION, PHYSIOLOGIC;

EID: 77955503583     PISSN: 09492321     EISSN: 2047783X     Source Type: Journal    
DOI: 10.1186/2047-783X-14-S4-259     Document Type: Article

References (31)

1. HIF-1 is required for solid tumor formation and embryonic vascularization. Ryan HE, Lo J, Johnson RS, EMBO J 1998 17 3005 15 10.1093/emboj/17.11.3005 9606183 (Pubitemid 28254373)
2. Angiogenesis in wound healing. Tonnesen MG, Feng X, Clark RA, J Investig Dermatol Symp Proc 2000 5 40 6 10.1046/j.1087-0024.2000.00014.x 11147674 (Pubitemid 32044088)
3. The codependence of angiogenesis and chronic inflammation. Jackson JR, Seed MP, Kircher CH, Willoughby DA, Winkler JD, FASEB J 1997 11 457 65 9194526 (Pubitemid 27259987)
4. Angiogenesis in cancer and other diseases. Carmeliet P, Jain RK, Nature 2000 407 249 57 10.1038/35025220 11001068
5. Molecular angiogenesis. Klagsbrun M, Moses MA, Chem Biol 1999 6 217 R24 10.1016/S1074-5521(99)80081-7 10421764 (Pubitemid 29380763)
6. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Hanahan D, Folkman J, Cell 1996 86 353 64 10.1016/S0092-8674(00) 80108-7 8756718 (Pubitemid 26272076)
7. Interstitial vascularity in fibrosing alveolitis. Renzoni EA, Walsh DA, Salmon M, Sestini P, Nicholson AG, Veeraraghavan S, Bishop AE, Romanska HM, Pantelidis P, Black CM, du Bois RM, Am J Respir Crit Care Med 2003 167 438 43 10.1164/rccm.200202-135OC 12406847 (Pubitemid 36216429)
8. Angiogenic cytokines in patients with idiopathic interstitial pneumonia. Simler NR, Brenchley PE, Horrocks AW, Greaves SM, Hasleton PS, Egan JJ, Thorax 2004 59 581 5 10.1136/thx.2003.009860 15223865 (Pubitemid 38901516)
9. CXC chemokines in vascular remodeling related to pulmonary fibrosis. Strieter RM, Belperio JA, Keane MP, Am J Respir Cell Mol Biol 2003 29 Suppl 3 67 S9 14503558
10. Modulatory effect of sera from sarcoidosis patients on mononuclear cells-induced angiogenesis. Zielonka TM, Demkow U, Bialas B, Filewska M, Zycinska K, Radzikowska E, Szopinski J, Skopinska-Rázewska E, J Physiol Pharmacol 2007 58 Suppl 5 753 66 18204190 (Pubitemid 351346725)
11. Modulatory effect of sera from patients with various types of pulmonary fibrosis on mononuclear cells-induced angiogenesis in relation to pulmonary function. Zielonka TM, Demkow U, Filewska M, Bialas-Chromiec B, Zycinska K, Szopinski J, Remiszewski P, Rowinska-Zakrzewska E, Wardyn KA, Skopinska-Rozewska E, J Physiol Pharmacol 2008 59 Suppl 6 771 9 19218704
12. Angiogenic activity of sera from silicosis and pulmonary Langerhans cell histiocytosis patients in relation to lung function tests. Zielonka TM, Demkow U, Filewska M, Bialas-Chromiec B, Zycinska K, Radzikowska E, Korzeniowska M, Wardyn KA, Kus J, Skopinska-Rozewska E, J Physiol Pharmacol 2008 59 Suppl 6 781 9 19218705
13. Functional impairment in fibrosing alveolitis: relationship to reversible disease on thin section computed tomography. Wells AU, Rubens MB, du Bois RM, Hansell DM, Eur Respir J 1997 10 280 5 10.1183/09031936.97.10020280 9042621 (Pubitemid 27063840)
14. Statement on sarcoidosis. ATS/ERS/WASOG, Sarcoidosis Vasc Diffuse Lung Dis 1999 16 149 73 10560120
15. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS) and the European Respiratory Society (ERS). American Thoracic Society, Am J Respir Crit Care Med 2000 161 646 64 10673212
16. Clinical diagnosis of hypersensitivity pneumonitis. Lacasse Y, Selman M, Costabel U, Dalphin JC, Ando M, Morell F, Erkinjuntti-Pekkanen R, Muller N, Colby TV, Schuyler M, Cormier Y, HP Study Group, Am J Respir Crit Care Med 2003 168 952 8 10.1164/rccm.200301-137OC 12842854 (Pubitemid 37267173)
17. International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. American Thoracic Society/European Respiratory Society, Am J Respir Crit Care Med 2002 165 277 304 11790668
18. Lymphocyte-induced angiogenesis: a quantitative and sensitive assay for the graft-versushost reaction. Sidky YA, Auerbach R, J Exp Med 1975 141 1084 100 10.1084/jem.141.5.1084 236355
19. Interstitial lung diseases: an epidemiological over-view. Demedts M, Wells AU, Anto JM, Costabel U, Hubbard R, Cullinan P, Slabbynck H, Rizzato G, Poletti V, Verbeken EK, Thomeer MJ, Kokarinen J, Dalphin JC, Taylor AN, Eur Respir J 2001 18 Suppl 32 2s 16s (Pubitemid 34755182)
20. Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR)-dependent signaling. Humar R, Kiefer FN, Berns H, Resink JT, Battegay EJ, FASEB J 2002 16 771 80 10.1096/fj.01-0658com 12039858 (Pubitemid 34615125)
21. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Selman M, King TE, Pardo A, Ann Intern Med 2001 134 136 51 11177318 (Pubitemid 32096342)
22. Angiogenesis in interstitial lung diseases: a pathogenetic hallmark or a bystander? Tzouvelekis A, Anevlavis S, Bouros D, Respir Res 2006 DOI: 10.1186/1465-9921-7-82 (Pubitemid 44150690)
23. Precapillary systemic-pulmonary anastomoses. Turner-Warwick M, Thorax 1963 18 225 37 10.1136/thx.18.3.225 14064617
24. The CXC chemokines, IL-8 and IP-10, regulate angiogenic activity in idiopathic pulmonary fibrosis. Keane MP, Arenberg DA, Lynch JP, Whyte RI, Iannettoni MD, Burdick MD, Wilke CA, Morris SB, Glass MC, DiGiovine B, J Immunol 1997 159 1437 43 9233641 (Pubitemid 127484123)
25. VEGF and bFGF are highly expressed in intraluminal fibromyxoid lesions in bronchiolitis obliterans organizing pneumonia. Lappi-Blanco E, Soini Y, Kinnula V, Paakko P, J Pathol 2002 196 220 27 10.1002/path.1038 11793374 (Pubitemid 34110904)
26. Neutralization of the CXC chemokine, macrophage inflammatory protein-2, attenuates bleomycin-induced pulmonary fibrosis. Keane MP, Belperio JA, Moore TA, Moore BB, Arenberg DA, Smith RE, Burdick MD, Kunkel SL, Strieter RM, J Immunol 1999 162 5511 8 10228032 (Pubitemid 29307163)
27. Angiogenesis in hypersensitivity pneumonitis. Navarro C, Ruiz V, Gaxiola M, Carrillo G, Selman M, Arch Physiol Biochem 2003 111 365 8 15764076 (Pubitemid 40292081)
28. Increase of lung neutrophils in hypersensitivity pneumonitis is associated with lung fibrosis. Pardo A, Barrios R, Gaxiola M, Segura-Valdez L, Carrillo G, Estrada A, Mejia M, Selman M, Am J Respir Crit Care Med 2000 161 1698 1704 10806177 (Pubitemid 30329050)
29. Angiogenesis in rheumatoid arthritis. Szekanecz Z, Szegedi G, Koch AE, J Invest Med 1998 46 27 41
30. Serum levels of vascular endothelial growth factor (VEGF) are markedly elevated in patients with Wegener's granulomatosis. Li CG, Reynolds I, Ponting JM, Holt PJ, Hillarby MC, Kumar S, Br J Rheumatol 1998 37 1303 6 10.1093/rheumatology/37.12.1303 9973154
31. Angiogenesis in the mouse lung. Mitzner W, Lee W, Georgakopoulos D, Wagner E, Am J Pathol 2000 157 93 101 10.1016/S0002-9440(10)64521-X 10880380 (Pubitemid 30641728)